Invalidity dossier
US 8669290
Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Current assignee: Senju Pharmaceutical Co Ltd
Added 9/23/2026, 3:38:17 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US8669290B2
Title: Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Patent number: US8669290B2 | Application: US13/687,242 | Publication: US20130090384A1
Inventor(s): Shirou Sawa; Shuhei Fujita
Assignee: Senju Pharmaceutical Co Ltd (original and current assignee as listed)
Key dates:
- Prior art date / priority date: 2003-01-21
- Filing date: 2012-11-28
- Publication date: 2014-03-11
- Anticipated expiration: 2024-01-16
- Legal status: Expired – Fee Related
Purpose / plain-language scope:
The patent concerns an aqueous (water-based) liquid preparation containing the compound 2-amino-3-(4-bromobenzoyl)phenylacetic acid. The chemical structure indexed for the active compound is NC1=C(CC(=O)O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 (PubChem CID-style identifier ZBPLOVFIXSTCRZ-UHFFFAOYSA-N). The disclosures reference a "hydrate" form among the prior-art keywords. The excerpt describes the preparation as an aqueous liquid and classifies it for medical use, with classifications covering solutions (A61K9/08), eye/ophthalmic application (A61K9/0048), nose (A61K9/0043), and therapeutic categories including ophthalmic agents (A61P27/02), otologicals (A61P27/16), and non-steroidal anti-inflammatory agents (A61P29/00).
The excerpt identifies the active ingredient by name and formula but does not set out the claims, dosage ranges, excipients, pH, or manufacturing steps.
What the excerpt does not establish:
This overview is limited to the supplied search-result text. The excerpt provides no claim language, no examples, no efficacy or safety data, and no specification text beyond classifications and keywords. It does not establish the precise scope of the claims, the concentration or formulation of the active agent, or any clinical use. Statements about legal status, assignees, or dates are presented as listed assumptions in the source, not legal conclusions. Questions of validity, enforceability, prior art, ownership transfers, and litigation are outside the scope of this overview and are not addressed here.
Source: https://patents.google.com/patent/[US8669290](/patent/US8669290)/en
Generated 10/1/2026, 9:51:26 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 8669290. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.